Drug Profile
PT 11061
Latest Information Update: 08 Dec 1997
Price :
$50
*
At a glance
- Originator Isis Pharmaceuticals
- Class Antisense oligonucleotides
- Mechanism of Action RNA synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Transplant rejection
Most Recent Events
- 08 Dec 1997 Discontinued-Preclinical for Transplant rejection in USA (Unknown route)
- 11 Nov 1996 New profile
- 11 Nov 1996 Preclinical development for Transplant rejection in USA (Unknown route)